Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 189,304	$ 82,248
Accounts receivable	60,360	48,494
Prepaid clinical development costs	349	193
Inventories, net	84,469	65,623
Other prepaid and current assets	10,626	4,507
Total current assets	345,108	201,065
Property and equipment, net	307	0
Right of use operating lease assets	6,848	4,675
Intangible assets	56	56
Total assets	352,319	205,796
Current liabilities:
Accounts payable	47,669	31,718
Accrued clinical development costs	3,419	3,441
Accrued variable consideration	44,851	34,284
Other accrued liabilities	23,294	24,998
Revenue interest liability	0	34,828
Royalty sale liability	32,754	0
Deferred revenue from collaborations	20,672	25,402
Operating lease liabilities	2,679	1,553
Total current liabilities	175,338	156,224
Convertible notes, net of issuance costs	262,475	261,596
Revenue interest liability	0	239,950
Royalty sale liability	254,745	0
Operating lease liabilities	3,981	3,020
Total liabilities	696,539	660,790
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of June 30, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of June 30, 2024 and 480,000,000 shares authorized as of December 31, 2023; 196,619,606 shares issued at June 30, 2024 and 120,204,513 shares issued at December 31, 2023	195	118
Additional paid-in capital	1,260,770	1,149,170
Treasury stock, at cost; 1,994,198 shares at June 30, 2024 and December 31, 2023	(54,998)	(54,998)
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(1,550,187)	(1,549,284)
Total stockholders’ deficit	(344,220)	(454,994)
Total liabilities and stockholders’ deficit	$ 352,319	$ 205,796